Geode Capital Management LLC Raises Holdings in Precision BioSciences, Inc. (NASDAQ:DTIL)

Geode Capital Management LLC grew its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,974 shares of the company’s stock after purchasing an additional 19,088 shares during the period. Geode Capital Management LLC owned approximately 0.86% of Precision BioSciences worth $591,000 at the end of the most recent reporting period.

Separately, Janus Henderson Group PLC grew its position in Precision BioSciences by 10.9% in the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock worth $6,322,000 after acquiring an additional 68,943 shares in the last quarter. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on DTIL shares. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a research report on Friday.

Precision BioSciences Trading Up 26.7 %

DTIL opened at $5.70 on Friday. The firm has a market cap of $43.72 million, a P/E ratio of 95.02 and a beta of 1.41. Precision BioSciences, Inc. has a 12 month low of $3.61 and a 12 month high of $19.43. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The stock has a 50-day moving average of $6.09 and a 200 day moving average of $8.26.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.